In this video, Jeff Yu, MD, MS, highlighted the possible future directions of atopic dermatitis like further development of topical therapies, combination therapies and discussions of disease ...

Findings from a recent phase 3b/4 study of upadacitinib support a treat-to-target strategy for dose escalation or reduction ...

In this video, Jeff Yu, MD, MS, highlighted research from the Revolutionizing Atopic Dermatitis, or RAD, meeting and said the disease has “leapt to the forefront” of dermatologic diseases with ...

While some topical herbal therapies may provide benefit for patients with AD, systemic herbal therapies do not provide significant benefit.

Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) is one of the most promising stocks according to Wall Street analysts. On June 26, ...

Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.

The AJMC® Atopic Dermatitis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin condition that typically develops in early childhood.

The trial aims to assess the safety and efficacy of tralokinumab 300mg administered biweekly as a single agent.

Treatment with dupilumab is associated with weight gain in about two thirds of adults with atopic dermatitis over 3-6 months, according to a retrospective study.

Researchers have found in a new systematic review and meta-analysis that higher levels of environmental pollutants and ...

Atopic dermatitis is a very common skin disease found in both adults and children. In fact, up to 10 to 20 percent of the population at some point suffers from atopic dermatitis.

Atopic dermatitis and contact dermatitis may both have certain triggers that set off your flares. If you can avoid your triggers, you may be able to calm skin rashes or even prevent them.